Estrella Immunopharma Doses First Participant In Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Patients With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and
A company testing a new cancer medicine just gave it to its first patient in an official study. This is an early step that shows the medicine might be safe enough to try, but we won't know if it actually works for a long time.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.